According to Fortune Business Insights, the global Continuous Renal Replacement Therapy (CRRT) market was valued at USD 1.16 billion in 2024. The market is projected to grow from USD 1.25 billion in 2025 to USD 2.14 billion by 2032, exhibiting a CAGR of 8.0% during the forecast period. In 2024, North America dominated the CRRT market with a market share of 39.66%.
Leading Players in the CRRT Market
- Baxter (U.S.)
- B Braun SE (Germany)
- Fresenius Medical Care AG & Co. KGaA (Germany)
- Asahi Kasei Medical Co., Ltd. (Japan)
- NIPRO (Japan)
- TORAY MEDICAL CO., LTD. (Japan)
- Nikkiso Co., Ltd. (Japan)
- Medtronic (Ireland)
Key Industry Development
In December 2023, Cheshire Medical Center, part of Dartmouth Health, began offering CRRT to ICU patients suffering from kidney failure—reinforcing the essential role of CRRT in intensive care .
Market Drivers & Restraints
Market Drivers
- High AKI Incidence & ICU Admissions: Acute Kidney Injury is on the rise, especially among critically ill and sepsis patients. ICU admissions also surged during the COVID‑19 pandemic, with AKI a key complication .
- Technological Innovations: Systems like Baxter’s PrisMax 2 launch in 2021 and advances in fluid management, automation, and AI-enabled remote monitoring enhance CRRT effectiveness .
Market Restraints
- High Cost of CRRT: CRRT is significantly more expensive than intermittent dialysis—a U.S. survey estimates daily costs of ~USD 870 vs. USD 270, impacting adoption in cost-sensitive settings .
- Operational Complexity & Expertise Needs: CRRT setup requires skilled personnel and strict protocols. Plus, pediatric CRRT systems now face additional regulatory scrutiny (e.g., FDA’s Class II classification in Sept 2024) .